Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia

BACKGROUND: Evidence from prospective cardiovascular (CV) outcome trials in type 2 diabetes (T2DM) patients supports the use of sodium–glucose co-transporter-2 inhibitors (SGLT2i) to reduce the risk of CV events. In this study, we compared the risk of several CV outcomes between new users of SGLT2i...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cardiovasc Diabetol
Main Authors: Real, Jordi, Vlacho, Bogdan, Ortega, Emilio, Vallés, Joan Antoni, Mata-Cases, Manel, Castelblanco, Esmeralda, Wittbrodt, Eric T., Fenici, Peter, Kosiborod, Mikhail, Mauricio, Dídac, Franch-Nadal, Josep
格式: Artigo
語言:Inglês
出版: BioMed Central 2021
主題:
Original Investigation
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8272340/
https://ncbi.nlm.nih.gov/pubmed/34243779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01323-5
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍